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Adenovirus-mediated kallikrein gene delivery reverses salt-in-
duced renal injury in Dahl salt-sensitive rats.
Background. The tissue kallikrein-kinin system has been shown
to play a role in cardiac and renal functions. In this study, we
investigated the ability of kallikrein gene delivery to reverse
salt-induced cardiac hypertrophy and renal injury in Dahl salt-
sensitive rats.
Methods. Adenovirus harboring the human tissue kallikrein
gene, Ad.CMV-cHK, was delivered intravenously into Dahl salt-
sensitive rats suffering from hypertension, cardiac hypertrophy
and renal damage induced by a high salt diet (4% NaCl) for four
weeks.
Results. Expression of human kallikrein mRNA was detected in
rat kidney, heart, aorta and liver, and immunoreactive human
kallikrein levels were measured in the serum and urine of rats
receiving gene delivery. A single injection of Ad.CMV-cHK
caused a significant reduction of blood pressure for more than two
weeks. Kallikrein gene transfer caused left ventricular mass
reduction and elevated glomerular filtration rate, renal blood
flow, urinary excretion, urinary kinin, nitrite/nitrate content,
cGMP and cAMP levels. Morphological investigations showed
that kallikrein gene transfer caused a significant reversal in
salt-induced tissue and organ damage. In the heart, cardiac
hypertrophy and fibrosis were reduced, and in the kidney, both
glomerular sclerotic lesions and tubular damage were reversed.
Conclusions. Adenovirus-mediated kallikrein gene delivery is
effective in reversing salt-induced cardiac hypertrophy and renal
injury in Dahl-salt sensitive rats.
The tissue kallikrein-kinin system has been shown to play
a role in hypertensive and renal diseases [1, 2]. Extensive
clinical studies showed that urinary kallikrein levels are
inversely correlated with blood pressure [3–5]. Since uri-
nary kallikrein originates from the kidney, the correlation
between high blood pressure and reduced urinary kallikrein
levels suggests the participation of renal kallikrein in blood
pressure homeostasis. Although these clinical studies have
implicated a role of renal kallikrein in hypertension, the
results are based on random population samples which do
not lend themselves to rigorous genetic analyses. A study
aimed at identifying genetic factors associated with cardio-
vascular risks using family pedigrees concluded that a
dominant gene expressed as renal or urinary kallikrein may
be associated with a reduced risk of hypertension [6].
Reduced urinary kallikrein excretion has also been de-
scribed in a number of genetically hypertensive rats [7–10].
To evaluate the role of tissue kallikrein in blood pressure
regulation as well as cardiovascular and renal function, we
have created animal models with altered kallikrein gene
expression. We showed that transgenic mice overexpressing
human tissue kallikrein exhibit a life-long reduction in
blood pressure [11, 12]. These studies provide direct evi-
dence linking alteration of tissue kallikrein gene expression
and blood pressure regulation. To further evaluate the
potential of kallikrein gene therapy in hypertension, we
introduced the human tissue kallikrein gene into various
hypertensive rat models by somatic gene delivery [13–16].
A single injection of the human tissue kallikrein gene in the
form of naked DNA or in an adenovirus vector induces a
prolonged blood pressure reduction in genetically hyper-
tensive or experimentally-induced hypertension for several
weeks. These results showed that a continuous supply of
exogenous tissue kallikrein via gene delivery exhibits pro-
tective effects in the development of high blood pressure.
A continuous supply of kallikrein has also been shown to
have protective effects on renal function as long-term
infusion of purified tissue kallikrein attenuates glomerular
sclerotic lesions and tubular injury in hypertensive Dahl
salt-sensitive (Dahl-SS) rats without causing an apparent
blood pressure reduction [17]. Renal kallikrein content of
Dahl-SS rats was shown to be lower than that of Dahl
salt-resistant rats (Dahl-SR) on high, normal, and low salt
diets [18]. A previous study showed that renal or urinary
kallikrein levels of Dahl-SS rats on a high-salt diet (8%
NaCl) were lower than for rats on a normal diet [19]. Lower
kallikrein or kinin levels in Dahl-SS rats on a high salt diet
may contribute to their high blood pressure and these
findings suggest that low renal kallikrein levels may also
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contribute to salt-related renal diseases. Our recent studies
showed that kallikrein gene delivery offers protection if
administered prior to the development of cardiac hypertro-
phy and renal injury in Dahl-SS rats fed a high salt diet [20].
It is unclear if existing tissue damage can be reversed by this
novel technique. In this study, we investigated this possibil-
ity and found that kallikrein gene delivery in Dahl-SS rats
caused a reversal in cardiac hypertrophy and renal injury
induced by a high salt diet prior to gene therapy. These
findings provide important information for future thera-
peutic applications in treating salt-induced end-stage renal
diseases.
METHODS
Animal treatment
Dahl salt-sensitive rats (male, four weeks old) were
purchased from Sprague-Dawley (Harlan, Indianapolis, IN,
USA). Rats were divided into three groups. The control
group was fed a standard rat chow (0.4% NaCl) (Harlan
Teklad, Madison, WI, USA). The experimental groups
were fed throughout the study with a high salt diet (4%
NaCl) (Harlan Teklad). All rats had free access to water.
Throughout the study period, all animals were housed in a
room that was kept at constant temperature (25 6 1°C) and
humidity (60 6 5%) and was lighted automatically from
8:00 a.m. to 8:00 p.m. All procedures complied with the
standards for care and use of animal subjects as stated in
the Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Resources, National Academy of
Sciences, Bethesda, MD, USA).
Preparation of replication-deficient adenoviral vector,
Ad.CMV-cHK
Adenovirus vector Ad.CMV-cHK was prepared as pre-
viously described [20] in which the expression of human
tissue kallikrein cDNA was under the control of the
cytomegalovirus (CMV) enhancer/promoter and was fol-
lowed by a bovine growth hormone (BGH) poly A signal
sequence. Adenovirus harboring the LacZ gene under the
control of the CMV enhancer/promoter (Ad.CMV-LacZ)
was purchased from the Institute for Human Gene Therapy
(Wistar Institute, Philadelphia, PA, USA).
Intravenous delivery of adenoviral vectors Ad.CMV-cHK
and Ad.CMV-LacZ
Seven Dahl-SS rats from experimental groups, which
were fed a high salt diet containing 4% NaCl, were
intravenously (i.v.) injected with either Ad.CMV-cHK or
Ad.CMV-LacZ at a dosage of 1.2 3 1010 pfu (plaque
formation units) per rat through the tail vein. During the
experimental period, blood was collected daily from the tail
vein after injection. Rat serum samples were frozen at
280°C until the expression level of immunoreactive human
tissue kallikrein could be determined.
Blood pressure measurement
The systolic blood pressure of rats was measured with a
manometer-tachometer (Nastume KN-210; Nastume Sei-
sakusho Co. Ltd., Tokyo, Japan) using the tail-cuff method
[13]. Unanesthetized rats were introduced into a plastic
holder mounted on a thermostatically controlled warm
plate, which was maintained at 33 to 35°C during measure-
ments. An average of ten readings was taken for each
animal after they became acclimated to the environment.
Urine collection and analysis of physiological parameters
Twenty-four-hour urine of rats was collected in meta-
bolic cages at seven days after gene delivery. Rats were fed
a 4% NaCl diet for three hours before placing them in
metabolic cages that were supplied with drinking bottles.
To eliminate contamination of urine samples, animals
received only water during the 24-hour collection period.
Urine was collected and centrifuged in a microfuge at
1,000 3 g to remove particles. The volume of the superna-
tant was measured and stored at 220°C until analysis for
kinin, nitrite/nitrate (NOx), 39,59-cyclic adenosine mono-
phosphate (cAMP) and cyclic guanosine monophosphate
(cGMP) and human tissue kallikrein levels.
Tissue preparation
At the end of the experiment, all rats were anesthetized
intraperitoneally with pentobarbital at a dose of 50 mg/kg
body wt. Blood samples were collected by direct cardiac
puncture and chilled at 4°C overnight. The blood samples
were centrifuged at 1,000 3 g for 20 minutes and sera were
removed and frozen at 220°C. At the same time, rats were
perfused with normal saline (0.9% NaCl) via the heart. The
whole heart, left ventricle, left and right kidneys were
removed, blotted and weighed. Tissues of interest were
removed and total RNAs were extracted by the trizol
method (BRL, Gaitherburg, MO, USA). The extracted
RNA was quantified spectrophotometrically by absorbance
at 260 nm, dissolved in diethyl pyrocarbonate-treated wa-
ter, and stored at 280°C for further use.
RT-PCR Southern blot analysis of human tissue
kallikrein mRNA
Reverse transcription-polymerase chain reaction (RT-
PCR) Southern blot analysis using specific oligonucleotide
probes for human tissue kallikrein (59-primer, 59-AACA-
CAGCCCAGTTTGT-39; 39 primer, 59-CTTCACATAA-
GACAGCA-39; internal probe, 59-GACCTCAAAATCCT-
GCC-39) was performed as previously described [20].
Enzyme-linked immunosorbent assay (ELISA) for human
tissue kallikrein
The levels of immunoreactive tissue kallikrein in rat
serum and urine were measured by an ELISA specific for
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human tissue kallikrein as previously described [20]. Hu-
man tissue kallikrein standard ranged from 0.4 to 25 ng/ml.
Since the antibody only recognizes active kallikrein [20],
the immunoreactive kallikrein levels determined by ELISA
represent active kallikrein.
Assays of urinary kinin, cGMP and cAMP levels
Urinary kinin levels were determined by a direct kinin
RIA as described [20]. The assays for cGMP and cAMP
were conducted according to previously described proce-
dures [21, 22].
Measurement of glomerular filtration rate and renal
blood flow
Rats were anesthetized with pentobarbital (50 mg/kg,
i.p.) and placed on a heating pad for maintenance of body
temperature at 37°C. After tracheotomy, a cannula was
placed in the jugular vein for infusion of fluids and drugs. A
cannula was placed in the right femoral artery for the
measurement of blood pressure and for blood sampling.
The bladder was cannulated to allow urine collection from
the right kidney. The left kidney was exposed by a flank
incision, freed of perirenal tissue, placed in a Lucite cup,
and bathed in 0.9% NaCl and then the ureter was cannu-
lated. Hydropenic preparations were maintained by an
intravenous injection of 1.2 ml of 0.9% NaCl containing
10% polyfructosan (Inutest, Laevosan, Linz, Austria) and
2% para-aminohippuric acid (PAH; Merck Sharp &
Dohme, West Point, PA, USA) via the cannula in the
jugular vein during the experimental period. Forty-five
minutes were allowed for the preparation to reach a steady
state. Timed urine collections were obtained, with blood
(0.6 ml) collected between clearance periods. For mainte-
nance of hematocrit, red blood cells from each blood
sample were reconstituted to the same volume with 0.9%
NaCl and reinjected through the arterial cannula. At the
end of each experiment, kidneys were excised, blotted, and
weighed. Urine volume was determined gravimetrically.
Polyfructosan and PAH concentrations were determined by
modified anthrone and colorimetric methods, respectively
[23]. Glomerular filtration rate (GFR) and renal plasma
flow (RPF) were determined from the clearance of poly-
fructosan and PAH, respectively. Renal blood flow (RBF)
was calculated from RPF and hematocrit. Clearance data
were normalized to kidney weight.
Morphological and histological investigation of the heart
and kidney
Rats were anesthetized with pentobarbital (50 mg/kg
body wt) and hearts and kidneys were removed, cleaned,
washed in saline, blotted and weighed. Slides of the kidney
and heart were preserved in 4% buffered formaldehyde
solution and embedded in paraffin. Five micrometer sec-
tions were cut with a microtome, mounted on glass slides
and stained with hematoxylin-eosin, then analyzed micro-
scopically and morphometrically. Histological sections of
rat heart muscle were analyzed from all experimental
groups. Cardiac myocyte diameters were measured in two
perpendicular directions using an ocular micrometer with
an engraved measuring scale [20]. The ocular micrometer
was calibrated against a stage micrometer, and conversion
factors were calculated for low (34 objective) and high
(345 objective) magnifications. Cardiac myocytes were
judged to be cut in cross section when the shorter measure-
ment was not more than 2 mm wider than the longer
measurement. The average of the two measurements was
then recorded as the cross-sectional diameter of the mea-
sured myocyte. The mean diameter of 200 cardiomyocytes
in each group was measured with a calibrated eyepiece at a
magnification of 3450. All sections were evaluated in a
blind study in which knowledge of the group to which the
measurements belonged was revealed only after the data
were tabulated.
Statistical analysis
Data were analyzed using standard statistical methods.
Repeated blood pressure measurements at each time point
were taken for comparison between control and experi-
mental groups. The blood pressure data were analyzed with
the use of ANOVA and Fisher’s protected least significant
differences. Group data are expressed as mean 6 SEM.
Values were considered significantly different at a value of
P , 0.05.
RESULTS
Kallikrein gene delivery reduces blood pressure in
hypertensive Dahl-SS rats on a high salt diet
Dahl-SS rats (four weeks old) were fed a high salt (4%
NaCl) diet or normal control diet (rat chow, 0.4% NaCl)
Fig. 1. Systolic blood pressure of Dahl-SS rats after i.v. injection of
Ad.CMV-cHK and Ad.CMV-LacZ. Control, Dahl-SS rats (M) were fed a
normal salt diet (0.4% NaCl); Dahl-SS rats were fed a high salt diet (4%
NaCl), receiving control adenovirus, Ad.CMV-LacZ (u) or adenovirus
carrying the human kallikrein gene, Ad.CMV-cHK (f). Blood pressure
values are expressed as mean 6 SEM (N 5 6). Standard errors are shown
by bars.
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for four weeks. The blood pressure of Dahl-SS rats on a 4%
NaCl diet increased with the change in dietary salt intake
and the differences between low and high salt groups
reached over 50 mm Hg prior to kallikrein gene delivery.
Rats (eight weeks old) on a high salt diet were then divided
into two groups and injected via the tail vein with either a
viral vector containing the human tissue kallikrein gene
(Ad.CMV-cHK) or a control vector containing the bacte-
rial LacZ gene (Ad.CMV-LacZ). The blood pressure of
Dahl-SS rats fed a high salt diet increased markedly as
compared to rats on a low salt diet (0.4% NaCl). Figure 1
shows systolic blood pressures of Dahl-SS rats fed a high
salt diet injected with the virus carrying the kallikrein gene
or control adenovirus. Delivery of the human tissue kal-
likrein gene resulted in a significant reduction of blood
pressure in salt-induced hypertensive Dahl-SS rats at 4 and
11 days post-injection. The difference in blood pressure
between the control group and the group receiving kal-
likrein gene delivery persisted for more than two weeks
post-injection.
Expression of human tissue kallikrein after gene delivery
Expression of the human tissue kallikrein mRNA in
Dahl-SS rats after gene delivery was detected by RT-PCR
followed by Southern blot analysis using three oligonucle-
otides specific for human tissue kallikrein. Total RNAs
were prepared from tissues of rats 12 days after gene
delivery. Figure 2 shows that human kallikrein mRNA can
be detected in the kidney, heart, aorta and liver (upper
panel, left). The RT-PCR products from rats receiving the
Ad.CMV-LacZ gene did not hybridize to the human tissue
kallikrein gene probe (upper panel, right). Similar levels of
b-actin mRNA were detected in tissues of both experimen-
tal and control groups, verifying the quality of RNA in
these samples (lower panel). These results indicate that
Southern blot analysis is specific for human tissue kallikrein
and that endogenous rat tissue kallikrein family members
do not interfere with the assay.
Following intravenous injection of Ad.CMV-cHK ade-
novirus, human tissue kallikrein levels in rat sera and urine,
collected at different time periods, were measured by
ELISA. The highest level of immunoreactive human tissue
kallikrein in rat serum was 254.1 6 0.9 ng/ml on the third
day after gene delivery (Table 1). Also, immunoreactive
human tissue kallikrein was measured in the urine of
Dahl-SS rats receiving Ad.CMV-cHK (16.3 6 3.6 mg/100 g
body wt/day) but not in the urine of control rats receiving
Ad.CMV-LacZ (Table 1). Linear displacement curves for
immunoreactive kallikrein in rat sera and urine were
Fig. 2. Expression of human kallikrein mRNA
in Dahl-SS rats after human kallikrein gene
delivery. The rats were sacrificed at 12 days
post injection and one mg of RNA was used for
RT-PCR. Human kallikrein mRNA in rat
tissues was amplified by a set of specific
oligonucleotides for human tissue kallikrein
which yielded a partial cDNA (503 bp) product
as shown in the upper panel. Rat b-actin
mRNA in rat tissues was amplified by a set of
specific oligonucleotides which yielded a 500 bp
product as shown in the lower panel. RNAs
from heart, kidney, aorta and liver of rats
receiving Ad.CMV-cHK of Ad.CMV-LacZ are
indicated in the Figure.
Table 1. Physiological analysis of Dahl salt-sensitive (SS) rats after kallikrein gene delivery
Variables
(1) Control
(0.4% NaCl)
(2) Ad.CMV-LacZ
(4% NaCl)
(3) Ad.CMV-cHK
(4% NaCl)
Urine volume ml/100 g body wt/day 7.4 6 1.0 9.2 6 1.5 13.7 6 0.7a
Urinary kinin ng/100 g body wt/day 5.4 6 0.9 12.0 6 4.4 35.4 6 9.0a
Urinary cGMP nmol/100 g body wt/day 11.5 6 2.9 11.4 6 2.0 17.6 6 1.9a
Urinary cAMP nmol/100 g body wt/day 12.9 6 1.0 15.1 6 0.9 18.5 6 1.0a
Urinary NOx content mmol/100 g body wt/day 1.45 6 0.53b 0.13 6 0.07 0.83 6 0.27a
Human kallikrein in serum ng/ml ND ND 254.1 6 0.9
Human kallikrein in urine mg/100 g body wt/day ND ND 16.3 6 3.6
Dahl-SS rats received either an Ad.CMV-cHK or Ad.CMV-LacZ injection at eight weeks of age and physiological measurements of rats were
performed seven days post gene delivery. Six rats from each group were measured for urine excretion, urinary kinin, cGMP, cAMP, NOx content, and
human kallikrein levels. Serum and urine samples were collected at 3 and 7 days, respectively, post gene delivery. Data were analyzed with ANOVA
and Fisher’s protected least significant differences. Values for each group are reported as mean 6 SEM (n 5 6). A value of P , 0.05 was interpreted
as indicating a significant difference between the groups. ND means not detectable.
a P , 0.05, (3) vs. (1) and (2)
b P , 0.01, (1) vs. (2)
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parallel with the standard curve of human tissue kallikrein,
indicating their immunological identity (data not shown).
Increased urinary excretion, kinin, nitrite\nitrate, cAMP,
cGMP and human tissue kallikrein levels in rats
receiving kallikrein gene delivery
Table 1 shows urinary excretion, kinin, nitrite/nitrate
(NOx) content, cAMP and cGMP levels in Dahl-SS rats at
seven days after gene delivery. Urine volume significantly
increased in rats receiving kallikrein gene delivery as
compared to control rats (13.7 6 0.7 vs. 9.2 6 1.5 ml/100 g
body wt per day, mean 6 SEM; N 5 6, P , 0.05). Urinary
kinin levels increased by three-fold after kallikrein gene
delivery as compared to control rats receiving Ad.CMV-
LacZ (35.4 6 9.0 vs. 12.0 6 4.4 ng/100 g body wt/day, N 5
5, P , 0.01). Urinary cAMP content increased significantly
after kallikrein gene delivery as compared to control rats
receiving Ad.CMV-LacZ (18.5 6 1.0 vs. 15.1 6 0.9 nmol/
100 g body wt/day, N 5 5, P , 0.05). Urinary cGMP levels
increased by 1.5-fold after kallikrein gene delivery as
compared to control rats receiving Ad.CMV-LacZ (17.6 6
1.9 vs. 11.4 6 2.0 nmol/100 g body wt/day, N 5 5, P , 0.01).
The urinary NOx content increase-d significantly after
kallikrein gene delivery as compared to control rats receiv-
ing the LacZ gene (0.83 6 0.27 vs. 0.13 6 0.07 mmol/100 g
body wt/day, N 5 4, P , 0.05).
Morphological changes in the heart after gene delivery
Figure 3A shows that the left ventricular weight is
significantly increased in Dahl-SS rats on a high salt diet
(4% NaCl) and injected with Ad.CMV-LacZ, as compared
to control rats given a normal salt diet (0.4% NaCl; 0.44 6
0.03 vs. 0.27 6 0.01 g per 100 g body wt, mean 6 SEM; N 5
6, P , 0.05). The left ventricular weight is significantly
decreased in Dahl-SS rats given 4% NaCl in the diet, but
injected with the tissue kallikrein gene (Ad.CMV-cHK) as
compared to rats injected with Ad.CMV-LacZ (0.38 6 0.04
vs. 0.44 6 0.03 g per 100 g body wt, mean 6 SEM; N 5 6, P ,
0.05). The high salt loading resulted in an enlarged average
diameter of cardiomyocytes in Dahl-SS rats with Ad.CMV-
LacZ injection (Fig. 3B). Figure 3B shows that the average
diameter of cardiomyocytes in the group receiving kal-
likrein gene transfer is significantly less than that of the
Ad.CMV-LacZ group (16.8 6 0.2 vs. 20.7 6 0.2 mm,
mean 6 SEM; N 5 200, P , 0.01). Cardiac myocytes of
animals on a normal salt diet (0.4% NaCl) appeared
normal and uniform in diameter (13.6 6 0.3 mm, mean 6
SEM; N 5 200; Fig. 4A), and were used as the baseline of
comparison for the high salt and gene-injected animals.
Diffuse interstitial proliferation was occasionally found in
the LacZ group (Fig. 4C) but not in the group receiving
kallikrein gene delivery (Fig. 4D). These results indicate
that salt-induced cardiac hypertrophy can be at least par-
tially reversed by kallikrein gene delivery in Dahl-SS rats.
Effects of kallikrein gene delivery on renal function
Glomerular filtration rate in Dahl-SS rats fed a high salt
diet and injected with control adenovirus Ad.CMV-LacZ
decreased by 35% compared to control rats on a normal
salt diet (0.31 6 0.13 vs. 0.91 6 0.08 ml/min/g kidney
weight, mean 6 SEM, N 5 4, P , 0.05). After kallikrein gene
delivery, glomerular filtration rate in Ad.CMV-cHK-in-
jected rats increased 2.1-fold as compared to those rats
injected with Ad.CMV-LacZ (0.66 6 0.07 vs. 0.31 6 0.13
ml/min/g kidney weight, mean 6 SEM, N 5 4, P , 0.05; Fig.
5). Similarly, renal blood flow in Dahl-SS rats fed a high salt
diet and injected with control adenovirus Ad.CMV-LacZ
was reduced 56% compared to control rats on a normal salt
diet (6.3 6 1.9 vs. 11.8 6 2.8 ml/min/g kidney weight,
Fig. 3. Left ventricular weight (A) and cardiomyocyte diameter (B) of
Dahl-SS rats after adenovirus-mediated kallikrein gene delivery. Control,
on a normal salt diet (0.4% NaCl); Ad.CMV-LacZ, (4% NaCl) receiving
control adenovirus carrying the LacZ gene; Ad.CMV-cHK, (4% NaCl)
receiving adenovirus carrying the human kallikrein gene.
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mean 6 SEM, N 5 4, P , 0.05) while kallikrein gene delivery
caused a 1.9-fold increase as compared to those rats
injected with Ad.CMV-LacZ (12.0 6 2.0 vs. 6.3 6 1.9
ml/min/g kidney weight, mean 6 SEM, N 5 4). These results
suggest that salt-induced renal damage leads to impairment
of glomerular filtration and renal blood flow, and that
kallikrein gene delivery causes reversal of renal damage.
Morphological changes in the kidney after gene delivery
Histological sections of the renal cortex (Fig. 6) and
medulla (Fig. 7), stained with hematoxylin and eosin,
showed some reversal of salt-induced renal injury in
Dahl-SS rats after kallikrein gene delivery. The cortex and
medulla of control Dahl-SS rats fed a normal salt diet
generally appeared normal, although small casts were
occasionally seen in medullary tubules (Figs. 6A and 7A).
High salt loading for four weeks resulted in significant renal
injury in both the cortex (Fig. 6) and the medulla (Fig. 7).
In the cortex of animals treated with either high salt alone
(four weeks) or high salt (six weeks) plus Ad.CMV-LacZ
for two weeks, damage was marked. This included de-
creased cell height and loss of brush borders in proximal
tubules (Fig. 6 B, C), thickening of glomerular basement
membranes with apparent glomerular sclerosis (Fig. 6C),
and focal accumulation of inflammatory cells. Sites of focal
(micro) hemorrhage were observed in Dahl-SS rats fed a
Fig. 4. Histological sections of heart stained with hematoxylin and eosin. (A) Control, Dahl-SS rat fed a normal salt diet (0.4% NaCl). (B) Dahl-SS
rat fed a high salt diet (4% NaCl) for four weeks. (C) Dahl-SS rat fed a high salt diet (4% NaCl) for four weeks, then given control adenovirus,
Ad.CMV-LacZ, two weeks prior to sacrifice. (D) Dahl-SS rat fed a high salt diet (4% NaCl) for four weeks, then given adenovirus, Ad.CMV-cHK
carrying the human tissue kallikrein gene, two weeks prior to sacrifice. Interstitial proliferation among enlarged cardiomyocytes is indicated by an arrow
(magnification 3125).
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high salt diet with and without Ad.CMV-LacZ for two
weeks (data not shown). Thickening of the arterial muscu-
lar layer (media) was obvious in both arcuate and interlob-
ular arteries in these animals. In Dahl-SS fed a high salt
diet and receiving kallikrein gene delivery (Ad.CMV-cHK),
proximal tubules and glomeruli exhibited much less dam-
age (Fig. 6D). No examples of hemorrhage were observed,
and inflammatory cell infiltration appeared decreased. The
arterial media was, in most cases, intermediate in thickness
between low-salt animals and high-salt animals receiving
Ad.CMV-LacZ for two weeks. In addition, it is intriguing
that mitoses were often seen in proximal tubule cells, and
occasionally in collecting duct cells in animals receiving
kallikrein gene delivery (Ad.CMV-cHK) (data not shown).
Figure 8 shows the protective effect of salt-induced
glomerular sclerosis in Dahl-SS rats after kallikrein gene
delivery. Of 75 glomeruli counted in control rats on a low
salt diet, only 1.0 6 1.3% exhibited sclerosis, compared
with 25.8 6 4.5% of 90 glomeruli counted in LacZ animals
fed a high salt diet for six weeks (P , 0.01). Of 70 glomeruli
counted in Dahl-SS rats receiving kallikrein gene therapy
and a high salt diet, 12.1 6 3.8% exhibited sclerotic changes
which is a 50% reduction of glomerular damage, compared
to the LacZ group (P , 0.05).
In the medulla (Fig. 7), salt loading resulted in the
development of large colloidal casts in renal tubules (com-
pare Fig. 7 A and B). These were also present in animals
receiving the control LacZ gene (Ad.CMV-LacZ; Fig. 7C),
but greatly reduced in rats receiving kallikrein gene deliv-
ery (Ad.CMV-cHK; Fig. 7D). These results indicate that
adenovirus-mediated kallikrein gene delivery improved
salt-induced renal dysfunction and partially reversed mor-
phological evidence of injury in Dahl-SS rats.
DISCUSSION
The present study shows that a continuous supply of
tissue kallikrein by somatic gene delivery reverses salt-
induced cardiac hypertrophy and renal injury in Dahl-SS
rats. A single injection of the adenovirus carrying the
human tissue kallikrein gene resulted in prolonged expres-
sion of exogenous kallikrein and increased kinin produc-
tion. In our previous study, we showed that blood pressure
reduction following kallikrein gene delivery was abolished
by aprotinin, a potent tissue kallikrein inhibitor, and by
Hoe 140, a specific bradykinin B2 receptor antagonist [13,
14]. These findings indicated that the protective effect
following kallikrein delivery may be mediated by activation
Fig. 5. Glomerular filtration rate (A) and renal blood flow (B) of Dahl-SS
rats after adenovirus-mediated kallikrein gene delivery. Control, on a
normal salt diet (0.4% NaCl); Ad.CMV-LacZ, (4% NaCl) receiving
control adenovirus carrying the LacZ gene; Ad.CMV-cHK, (4% NaCl)
receiving adenovirus carrying the human kallikrein gene. The renal
functional study was performed at two weeks after gene delivery.
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Fig. 6. Photomicrographs of representative hematoxylin and eosin-stained renal cortex sections. (A) Control, Dahl-SS rat, fed on a normal salt diet
(0.4% NaCl). (B) Dahl-SS rat, fed a high salt diet (4% NaCl) for four weeks. (C) Dahl-SS rat fed a high salt diet (4% NaCl) for four weeks, then given
control adenovirus, Ad.CMV-LacZ two weeks prior to sacrifice. (D) Dahl-SS rat fed a high salt diet (4% NaCl) for four weeks, then given adenovirus,
Ad.CMV-cHK carrying the human tissue kallikrein gene two weeks prior to sacrifice. Note dilated proximal tubules in B and C and glomerular sclerosis
in C (magnification 3100).
Fig. 7. Photomicrographs of representative hematoxylin and eosin-stained renal medulla sections. (A) Control, Dahl-SS rat fed a normal salt diet
(0.4% NaCl). (B) Dahl-SS rat, fed on a high salt diet (4% NaCl) for four weeks. (C) Dahl-SS rat fed a high salt diet (4% NaCl) for four weeks, then
given control adenovirus, Ad.CMV-LacZ, two weeks prior to sacrifice. (D) Dahl-SS rat fed a high salt diet (4% NaCl) for four weeks, then given
adenovirus, Ad.CMV-cHK carrying the human tissue kallikrein gene, two weeks prior to sacrifice. Note the large colloidal casts in medullary tubules
of animals given high salt (Fig. 7B) and high salt plus the Lac Z gene (Fig. 7C) (Magnification 350).
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of the kinin system. Increased urinary or renal kinin levels
are accompanied by increases in urinary NOx content,
cGMP and cAMP levels. The results suggest that the
protective effects of kinins on cardiac and renal functions
are mediated by the release of NOx and/or eicosanoids
resulting in increased cGMP and cAMP levels.
Urinary kallikrein excretion is markedly reduced in salt-
sensitive rats as compared with their salt-resistant counter-
parts [24, 25]. A previous study from this laboratory showed
that high NaCl intake suppresses the expression of the
kallikrein-kinin system in Dahl-SS rats [19]. When Dahl-SS
rats are placed on a high salt diet early in life, they develop
hypertension, cardiac hypertrophy and fibrosis as well as
renal injury, and die after six to eight weeks. In this study,
we placed four-week-old Dahl-SS rats on a high salt diet for
four weeks and showed that the blood pressure of these
animals reached a level that was 50 mm Hg higher than
those on a low salt diet. The high salt diet also resulted in
enlarged cardiomyocyte diameter, fibrosis and renal dam-
age in both cortex and medulla. The renal lesions induced
by high salt diet are of a focal nature and comparable to
malignant hypertensive renal disease seen in humans [26–
28]. Histological examinations revealed glomerular base-
ment membrane thickening, renal tubular dilation and
disruption of the proximal tubular brush border and pro-
tein casts in tubules. To rule out adenovirus as the cause of
these lesions, we carried out parallel studies using saline
injection to show that similar blood pressure rise and
histological lesions were produced in Dahl-SS rats by high
salt loading without virus (unpublished results). The ge-
netic basis for salt sensitivity in Dahl-SS rats is not known.
In the present study, we showed that a continuous supply of
exogenous kallikrein via gene delivery could regulate water,
electrolyte transport and salt handling and compensate for
the deficiency of the system in Dahl-SS rats after salt
loading.
It has been long suspected that enhanced kallikrein-kinin
function may alleviate some of the salt-induced damage in
Dahl-SS rats. The kallikrein-kinin system is well known for
its ability to cause vasodilation, which should provide direct
relief for salt-induced hypertension. Kinin has been shown
to be responsible for, at least in part, the cardioprotective
effect of angiotensin converting enzyme (ACE) inhibitors
on myocardial ischemia/reperfusion injury, since the car-
diac protective effects of ACE inhibition can be reversed by
Hoe140, a bradykinin B2 receptor antagonist [29–32].
Moreover, kinin is known to play a significant role in renal
sodium excretion and thus may be particularly relevant in
Dahl-SS rats under salt loading. A previous study showed
that infusion of purified rat tissue kallikrein via minipumps
attenutes renal injury in Dahl-SS rats after salt loading [17].
Collectively, these findings suggest that kallikrein’s protec-
tive effect in salt-induced cardiac and renal lesions may be
mediated by kinin. Taken together, it seems reasonable
that elevated activity of the kallikrein-kinin system may
offer cardiac protection and improve renal electrolyte
handling in this salt sensitive animal model. One possible
way to achieve this is by inhibiting kinin’s degradation
enzyme, kininase II, also known as ACE, using ACE
inhibitors. Alternatively, it has been shown that infusion of
purified rat tissue kallikrein resulted in attenuation of
glomerular sclerotic lesions and tubular injury in Dahl-SS
rats on a high salt diet [17]. Based on these observations, we
demonstrated that tissue kallikrein levels can be main-
tained on a long-term basis by somatic gene delivery in vivo
[13]. This technique was used to deliver the kallikrein gene
to Dahl-SS rats and shown to attenuate salt-induced renal
injury as well as cardiac hypertrophy if administered prior
to organ damage [20].
Our study was undertaken to determine if kallikrein gene
delivery can exert beneficial effects in animals with estab-
lished cardiac hypertrophy and renal injury. To accomplish
this aim, we delivered the kallikrein gene in an adenovirus
vector, Ad.CMV-cHK, into Dahl rats with existing cardio-
vascular and renal damage induced after four weeks of salt
loading. We demonstrated that kallikrein gene delivery was
able to alleviate cardiac hypertrophy and fibrosis, as there
was a reduction of cardiomyocyte diameter and left ven-
tricular weight. Most interestingly, we observed a reversal
of salt-induced glomerulosclerosis and proximal tubular
damage consistent with increases in glomerular filtration
rate and renal blood flow. In addition, human tissue
kallikrein gene expression in Dahl-SS rats also attenuated
salt-induced enlargement of renal mass [20]. It has been
shown that losartan is capable of reducing the rise in blood
Fig. 8. Protective effect against salt-induced glomerular sclerosis in
Dahl-SS rats after kallikrein gene delivery. Control, on a normal salt diet
(0.4% NaCl); Ad.CMV-LacZ, (4% NaCl) receiving control adenovirus
carrying the LacZ gene; Ad.CMV-cHK, (4% NaCl) receiving adenovirus
carrying the human kallikrein gene.
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pressure and glomerular sclerosis index in SHR that are
subjected to five-sixths nephrectomy, and that it decreases
interstitial fibrosis in cyclosporine-treated Sprague-Dawley
rats [33, 34]. These results indicated that losartan can
decrease blood pressures as well as ameliorate the organ
structural and functional changes. However, infusion of
purified kallikrein via minipumps was shown to attenuate
salt-induced glomerular sclerosis without affecting the
time-dependent elevation of blood pressure in Dahl-SS rats
[17]. Further studies in comparing the blood pressure-
lowering and renal protective effects of kallikrein gene
delivery versus hydralazine/furosemide should clarify the
question of whether the improvement in renal structure
and function following kallikrein gene delivery is a direct
effect of kinin action or a secondary effect due to blood
pressure reduction. Our present studies show that kal-
likrein gene delivery not only has a protective effect on
salt-induced cardiac and renal injury, but also could reverse
the damage that was already produced by a high salt
loading.
The mechanism by which exogenous tissue kallikrein
expression can prevent and even reverse salt-induced renal
injury is not clear at the present time. One potential
function of kallikrein is its ability to process growth factors
[35]. A number of peptide growth factors, such as platelet-
derived growth factor, fibroblast growth factor, transform-
ing growth factor-a, and epidermal growth factor, are
known to elicit mesangial cell proliferation in vitro [36].
Kallikrein may thus promote the regeneration of damaged
renal cells by accelerating the processes of growth factors.
Alternatively, elevated kinin levels caused by increased
production of kallikrein may be responsible for the ob-
served reversal of renal damage. Kinin’s actions are medi-
ated by B2 receptors that are widely distributed in the
kidney [37]. Kinin is known to stimulate the proliferation of
lymphocytes, fibroblasts and arterial smooth muscle cells as
well as mesangial cells [38–41]. The mitogenic activity of
kinin is abolished by a specific bradykinin receptor antag-
onist, Hoe140, indicating the involvement of the bradykinin
B2 receptor in mitogenic signal transduction [41]. Current
evidence suggests that kinin may play a role in the regula-
tion of DNA synthesis during later stages of nephrogenesis
and modulate segmental nephron maturation [41, 42]. The
functional significance of kinin’s ability to stimulate DNA
synthesis and cell proliferation has not been investigated in
the kidney of adult animals. In a preliminary histological
study, we have observed mitotic figures in proximal tubular
cells and occasionally in collecting ducts of rats receiving
kallikrein gene delivery in both salt-induced and drug-
induced renal injury following kallikrein gene delivery [43].
It is therefore likely that kinin-induced tubular cell prolif-
eration and regeneration may be responsible for the partial
reversal of renal damage. Further studies are needed to
verify this hypothesis. Also unresolved at this time is the
degree to which kallikrein gene delivery can reverse the
renal damage. We suspect that there is a point in renal
disease progression beyond which reversal is not possible.
Kallikrein gene delivery may be a good experimental
candidate in the treatment of salt-related hypertension as
well as cardiovascular and renal diseases. Currently, ade-
novirus-mediated gene delivery can achieve a high level of
expression but with limited duration, due mainly to immu-
nosurveillance by the host [44]. Future development of
adenovirus gene transfer combined with the administration
of immunosuppressive drugs or gene delivery with adeno-
associated viruses may offer alternatives for long-term and
high-efficiency therapeutic applications.
ACKNOWLEDGMENTS
This work was supported by National Institutes of Health grants
HL29397 and HL56686. We thank the Vector Core (Institute of Human
Gene Therapy) for providing the adenoviral shuttle plasmid pAdLink.1,
and the Wistar Institute, Institute of Human Gene Therapy, for providing
adenovirus Ad.CMV-LacZ and Ad.CMV-cHK. We thank Dr. Thomas H.
Hintze at New York Medical College for help in the measurement of NOx
content and Dr. Jo Anne Simson for critical reading of the manuscript and
for evaluation of histological changes in the kidney and heart.
Reprint requests to Lee Chao, Ph.D., Department of Biochemistry and
Molecular Biology, Medical University of South Carolina, 171 Ashley Avenue,
Charleston, South Carolina 29425-2211, USA.
E-mail: chaol@musc.edu
APPENDIX
Abbreviations used in this article are: ACE, angiotensin converting
enzyme; Ad.CMV-cHK, adenovirus harboring the human tissue kallikrein
gene; Ad.CMV-LacZ, adenovirus harboring the LacZ gene; BGH, bovine
growth hormone; cAMP, 39,59-cyclic adenosine monophosphate; cGMP,
cyclic guanosine monophosphate; CMV, cytomegalovirus; Dahl-SS, Dahl
salt-sensitive rats; Dahl-SR, Dahl salt-resistant rats; GFR, glomerular
filtration rate; NOx, nitrite/nitrate; PAH, para-aminohippuric acid; RPF,
renal plasma flow; RT-PCR, reverse transcription-polymerase chain reac-
tion.
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